RenovoRx announces acceptance for publication in The Oncologist

RenovoRx announced acceptance for publication in an international peer-reviewed journal, The Oncologist. The manuscript is titled, “Treatment of Locally Advanced Pancreatic Cancer Using Localized Trans-Arterial Micro Perfusion of Gemcitabine: Combined Analysis of RR1 and RR2” and expected in the Summer 2024 issue of The Oncologist. The manuscript’s lead author is Hassan Hatoum, MD, an oncologist and hematologist at the University of Oklahoma Health Sciences Center. The manuscript is a publication of clinical data, primarily survival, in LAPC patients undergoing TAMP treatment from the foundational studies conducted by the Company. RenovoRx investigated the drug-delivery of gemcitabine utilizing TAMP therapy platform in an early Phase I/II dose escalation safety study and acquired data from a post-marketing post-treatment observational registry study to evaluate the safety, tolerability and efficacy of the drug-device combination in LAPC. TAMP is being further evaluated in the ongoing pivotal Phase III randomized multi-center study, called TIGeR-PaC, evaluating its targeted approach to drug-delivery in LAPC. The study is comparing treatment with TAMP to the current standard of care of systemic intravenous chemotherapy.